Celator gains $20M round for cancer drug dev

Princeton, NJ-based Celator Pharmaceuticals has closed a $20 million Series D to back its development work on new cancer therapies. Its lead drug--CPX-351 (Cytarabine:Daunorubicin) Liposome Injection--is a treatment for acute myeloid leukemia. The round was led by a new investor, Thomas, McNerney & Partners, with participation by current investors Domain Associates, Ventures West Capital, Quaker BioVentures, TL Ventures, GrowthWorks Capital and BDC Venture Capital. "Earlier this year we announced that CPX-351 achieved a statistically significant improvement in complete remissions in newly diagnosed, elderly AML patients compared to the standard of care in a randomized Phase II study," said CEO said Scott Jackson. "We look forward to disclosing these results and other data later this year." Celator release

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.